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ABSTRACT 
 
Controlling metastatic and invasive tumors is the challenging part of 
treating cancer. The overall aim of this dissertation was to target these 
aggressive cells, called tumor-initiating cells (TICs). They exploit embryonic 
stem cell genes that should not otherwise be activated, allowing them their 
aggressive capabilities. Osteosarcoma is the most common bone cancer of 
children. Canine osteosarcoma was selected as the type of cancer to study 
because of its predictable and similar behavior to human osteosarcoma. Human 
osteosarcoma has an analogous gene signature to canine osteosarcoma, but a 
slightly prolonged length of remission due to more aggressive therapy. The 
goals accomplished in this dissertation were: 1) Optimized a method using 
epirubicin to enrich for TICs; 2) Used molecular techniques to determine the 
phenotypic differences in canine osteosarcoma TICs compared to typical cancer 
cells; 3) Evaluated two classes of drugs that specifically target the unique 
phenotypes in TICs in vitro and in vivo. These drug classes were smoothened-
inhibitors and Erb-B2 receptor tyrosine kinase 2 (HER2)-inhibitors. 
Epirubicin reliably enriched for phenotypically different TICs. Embryonic 
stem cell genes were expressed in TICs but not the differentiated tumor cells. A 
second embryonic stem cell pathway, the hedgehog pathway, is also 
upregulated in TICs. Two smoothened-inhibiting drugs, cyclopamine and 
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vismodegib, were used to block the hedgehog pathway in canine osteosarcoma 
cell lines in both in vitro and in vivo studies.  
The second target, HER2, was upregulated in both differentiated 
osteosarcoma cells and TICs. Lapatinib was used to block HER2 of TICs in vitro 
resulting in a significant cell death, which was demonstrated in viability assays. 
HER2 was also downregulated in RT-qPCR. Canine osteosarcoma mouse 
xenografts treated with lapatinib showed inhibition of tumor growth and tumor 
cell death.  
In conclusion, these studies have demonstrated the benefit of using 
therapies that target specific cancer cell subtypes through TIC-specific targets. 
Vismodegib performs best at slowing the growth of metastases formed by TICs, 
whereas lapatinib also causes TIC and differentiated tumor cell death. Future 
studies are intended to evaluate these drugs in dogs post-amputation. Human 
clinical trials will follow if successful. 
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NOMENCLATURE 
 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 
AKT1 V-Akt murine thymoma viral oncogene homolog 1 
AO/PI Acridine orange and propidium iodide 
CD34 CD34 molecule  
CD44 CD44 molecule 
CD117 V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene  
 homolog 
CD133 Prominin 1  
CSCs Cancer stem cells 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
FDA Federal Drug Administration 
G0  G0 resting phase 
GLI Glioma-associated oncogene family zinc finger transcription  
 factors  
GLI1 Glioma-associated oncogene family zinc finger 1 
GLI2 Glioma-associated oncogene family zinc finger 2 
GLI3 Glioma-associated oncogene family zinc finger 3 
H&E Hematoxylin and eosin 
HER2 Erb-B2 receptor tyrosine kinase 2 
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HH Hedgehog 
Ki-67 Marker of proliferation Ki-67 
LC Lethal concentration 
mRNA Messenger ribonucleic acid 
NANOG Nanog homeobox  
OCT4 POU class 5 homeobox 1 
P21 Cyclin-dependent kinase inhibitor 1A 
P27 Cyclin-dependent kinase inhibitor 1B 
P53 Tumor protein P53 
PBS Phosphate buffered saline 
PTCH1 Patched 1 
qPCR Quantitative real-time polymerase chain reaction 
R10 R10 complete medium 
RNA Ribonucleic acid 
RT-qPCR Reverse transcription real-time polymerase chain reaction 
SHH Sonic hedgehog 
SMO Smoothened 
SOX2 SRY (sex determining region Y)-box 2 
TICs Tumor-initiating cells 
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INTRODUCTION 
Preface 
The importance of targeting metastases 
For much of cancer research history, scientists and doctors have become 
successful at developing therapies that destroy primary tumors. Nevertheless, 
metastatic disease ultimately kills the patient. Over thirteen million people in the 
United States are currently battling cancer [1]. The American Cancer Society 
estimates that there will be 1,658,370 new cancer patients diagnosed and 
589,430 cancer deaths in 2015 [2]. Cancer is the second leading cause of death 
in the United States [3]. 
In veterinary medicine, cancer is even more prevalent in dogs. It is much 
more difficult to determine how many dogs are diagnosed with cancer annually. 
The most accurate estimate is four million dogs [4]. This estimate places dogs at 
a much higher cancer rate than humans given that there are fewer dogs in the 
United States (5,300/100,000 for dogs versus 500/100,000 for humans). This 
dissertation uses canine osteosarcoma as a model for metastatic disease. The 
information gathered from the drugs evaluated is intended to predict treatment 
response in both human and canine patients, and possibly other forms of 
metastatic cancer. 
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Osteosarcoma is a devastating bone cancer with a very poor prognosis 
[5-7]. The osteosarcoma pathogenesis is identical between dogs and humans, 
making dogs an excellent spontaneous model for study [8-10]. In both species, 
the primary tumor can be successfully managed. However, osteosarcoma 
tumors are known to seed metastases throughout the body early in the disease 
process, especially to the lungs, which results in death [11-13]. Drugs that 
prevent metastases from occurring or target metastases for death are highly 
desirable.  
 
Canine osteosarcoma 
Osteosarcoma is the most common primary bone tumor of dogs [8, 14-
19]. Large to giant breed dogs are more commonly affected. Affected breeds 
include greyhounds, rottweilers, German shepherds, doberman pinschers, 
Scottish deerhounds, great Danes, Afghan hounds, Irish wolfhounds, Borzois, 
Leonbergers, Irish setters, Saint Bernards, golden retrievers, Labrador 
retrievers, and mastiffs [12, 20-27]. The American Kennel Club Canine Health 
Foundation estimates that there are 10,000 new cases of canine osteosarcoma 
annually [28]. While others estimate up to 75,000 new cases of canine 
osteosarcoma are diagnosed annually [4]. National monitoring programs do not 
exist for dogs, so we may never know the exact number. But we can be certain 
that osteosarcoma is more prevalent and no less deadly in the canine population 
than in the human population. 
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With aggressive therapy only 50% of dogs will survive one year from 
diagnosis and less than 20% of dogs will survive two years from diagnosis [8, 
11-13, 29]. Aggressive therapy consists of amputation followed by adjuvant 
chemotherapy. The cause of death is rarely attributed to the primary tumor 
because most primary bone tumors are able to be surgically removed. Instead, 
the high mortality is due to metastases in the lungs, or less likely in other bones 
or soft tissues (i.e. lymph nodes, kidney, and liver) [8, 12, 30-33]. 
 
Human osteosarcoma 
Osteosarcoma is also the most common primary bone tumor of humans 
[34]. About 800 patients are diagnosed with osteosarcoma each year in the 
United States with half of that number comprised of children and teenagers [35]. 
Osteosarcoma patients are treated more aggressively and with more modern 
chemotherapeutic agents compared to dogs. Instead of amputation, they are 
often candidates for radical limb-sparing surgery [5, 7, 36]. Patients with 
localized osteosarcoma have a five-year disease-free survival rate of 71% [1]. 
Similar to dogs, approximately 20% of osteosarcoma patients have metastatic 
disease at diagnosis [37]. The five-year survival rate for patients that have 
metastatic disease at the time of diagnosis or patients with recurrent disease is 
poor [6, 38, 39]. 
Very few advances have been made in the treatment of osteosarcoma 
over the last 15-20 years. This is due to a lack of fundamental knowledge 
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regarding the tumorigenesis of osteosarcoma. It is crucial that we gain a better 
understanding of the mechanisms of tumor progression and metastasis in order 
to develop more effective therapies. Useful animal models are necessary to 
develop such therapies. 
 
Dogs as a spontaneous model of osteosarcoma 
Dogs and cats spontaneously develop cancers with the same genetic 
profiles, histologic diagnoses, and biological behavior as in humans. The tumor 
types include round cell neoplasms (i.e. non-Hodgkin’s lymphoma, leukemia, 
myeloma), sarcomas (i.e. osteosarcoma, soft tissue sarcomas, melanoma), 
brain tumors (i.e. meningioma, glioma/glioblastoma), and carcinomas (i.e. 
mammary/breast tumors, oral/nasal carcinomas, prostate cancer) [40]. This 
gives the researcher a wide variety of spontaneous tumors to evaluate. The 
canine spontaneous model for cancer cannot and should not replace rodent 
models. Murine models are known for being inherently inbred, but this provides 
accuracy and precision when controlled experimentation is necessary [41]. Less 
than 8% of treatments tested in rodents are successfully translated to human 
therapies [42]. This is due to vast differences between humans and rodent 
models. For example, mice can tolerate much higher doses of drugs [43]. 
Tumors grown in mouse xenografts may not vascularize properly or grow in the 
proper niche. Finally, the compromised immune system of murine models does 
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not mimic what happens in human cancer [44, 45]. Taken together, these things 
grossly overestimate potential clinical responses in humans. 
Unlike laboratory rodent models, our pets share the same environment as 
humans, and thus share the same environmental risk factors for cancer [46]. 
Dogs and cats have a heterogeneous genome, an intact immune system, and 
have been shown to respond to the same therapies used in humans [9, 10, 47]. 
Another advantage is their large size, which allows for multiple blood samplings, 
advanced diagnostic imaging, and realistic surgeries [10]. Human and canine 
genomes have more homology compared to human and murine genomes [48-
54]. All of these key features support using spontaneous canine models for 
evaluating the efficacy of treatments for extrapolation to human use. 
Human clinical trials start by using patients in the latest stages of disease 
and use a low dose of the therapy in question [55]. It takes many years and 
many cohorts of patients before the therapy can be evaluated for safety and 
efficacy at the optimal dosage. Dogs, on the other hand, have an accelerated 
aging process compared to humans and often an accelerated cancer 
progression [48, 56-58]. One year of a large-breed dog’s life is equivalent to six 
years of human life. This allows the researcher to translate canine one-year 
survival rates to predict human five-year survival rates in a specific study. Also, 
the therapeutic end-point results of canine clinical trials are gathered more 
quickly. Due to the lack of standards of care in veterinary medicine, owners are 
able and often willing to consent to clinical trials early in the disease process 
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allowing for treatment of naïve diseases with novel therapies [10]. Veterinarians 
are allowed to use more realistic doses and dose schedules for the therapy 
being evaluated in their canine patients. As stated earlier, dogs have a much 
higher prevalence of osteosarcoma compared to humans, which will allow trials 
to be adequately filled in a relatively short period of time. All of this adds up to 
knowing which therapies are most likely to help humans earlier and more 
accurately than if only experimental rodent models are used [47, 48, 59, 60]. 
Canine osteosarcoma closely mimics human osteosarcoma. The majority 
of osteosarcoma in both species develops at the metaphysis of long bones, 
metastases tend to occur in the lungs, and both species have similar genetic 
changes within the cancer [9, 10, 26, 48, 59, 61-68]. Dogs have already been 
used successfully as a model for human osteosarcoma [69]. Research dogs are 
a common species for toxicology studies, yet companion dogs are relatively new 
to being used to understand more about human cancer. The spontaneous model 
of canine osteosarcoma could lead to more effective therapies for dogs and 
humans after more studies are completed, especially for metastatic-targeting 
therapies. It is important for veterinarians to work closely with cancer 
researchers and physicians in this exciting endeavor.  
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Tumor-Initiating Cells in Cancer 
An all too common example of cancer 
It is important to briefly summarize the clinical presentation of cancer 
before discussing intricate details at the cellular level. Patients with late staged 
cancers involving macrometastases will not be discussed. The goal of this 
research is to target cells that form micrometastases, by either preventing the 
cells from proliferating or by eliminating them. This is representative of patients 
with early staged osteosarcoma. 
The initial treatment objective for aggressive cancers is to remove as 
many cancerous cells as possible. The patient receives some type of surgery, 
such as a limb amputation or debulking of the tumor. The cancer may eventually 
return in the form of metastases if no other treatments are performed. Deductive 
reasoning indicates that cancer cells had to have travelled to other organs 
before surgery in order for recurrence to take place at a later time distant from 
the primary tumor. These cells are not detected by modern diagnostic imaging. 
This implies that these metastatic cells clearly have the ability to remain 
microscopic and dormant until conditions improve at a later time. 
Survival times in patients may be improved with aggressive 
chemotherapy following surgery. Chemotherapy targets actively dividing cells 
[70]. As stated earlier, the metastatic cells are lying dormant; therefore, these 
drugs may not be effective in destroying them [71-77]. The end result is a 
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temporary remission with a cancer that is much more difficult to treat upon 
recurrence [78]. Ideally, patients should be treated with drugs that specifically 
target the dormant metastatic cells at the same time the primary tumor is being 
treated to prevent recurrence. Currently, no such treatment exists. 
 
The complexity of cancer 
 Young scholars are taught about clonal evolution and the hallmarks of 
cancer, but this information is basic when it comes to understanding cancer 
progression in its entirety [79-85]. Most cancers take years or decades to 
develop by means of clonal evolution [80]. As an oversimplified explanation, a 
cell first acquires a neoplastic mutation. This cell with its unique and 
advantageous phenotype becomes more populated through clonal expansion. 
Eventually a cell with the unique phenotype will acquire another mutation. 
Additional cycles of clonal expansion and mutations occur. Some of these 
mutations are harmless. Other mutations contribute to carcinogenesis, such as 
inactivation of tumor suppressor genes and oncogene activation [86]. Most 
tumors require two to eight of such mutations in order to become neoplastic [87]. 
Carcinogenesis is achieved when the cells have acquired favorable mutations 
that enhance functional capabilities, designated the hallmarks of cancer [79].  
These ten categories include sustaining proliferative signaling, insensitivity to 
anti-growth signals, tissue invasion/metastasis, limitless replicative potential, 
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inducing angiogenesis, evading apoptosis, tumor-promoting inflammation, and 
others (Table 1) [85].  
 
 
Figure 1. Clonal expansion in cancer depiction. Clonal evolution is composed 
of a series of mutations (lightning bolt) and expansions over time (top row). As 
carcinogenesis progresses, the cancer population becomes more 
heterogeneous (bottom row).  
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Table 1. The ten hallmarks of cancer adapted from Hanahan and Weinberg. [85] 
Acquired Capability Example 
Evading growth suppressors Dysregulation of tumor suppressor gene 
retinoblastoma protein 
Sustaining proliferative signaling Overexpression of epidermal growth 
factor 
Deregulating cellular energetics Increased glucose consumption by 
upregulating glucose transporter 1 
Resisting cell death Increased expression of the B-Cell 
CLL/Lymphoma 2 gene 
Genome instability and mutation Breakdown of breast cancer type 1 
susceptibility protein 
Inducing angiogenesis Overexpression of vascular endothelial 
growth factor 
Activating invasion and metastasis Activation of tumor-associated 
macrophages 
Tumor-promoting inflammation Tumor necrosis factor alpha 
overexpression 
 
Enabling replicative immortality Loss of tumor protein 53 (p53) 
 
Avoiding immune destruction Activation of the indoleamine 2,3-
dioxygenase pathway 
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 The last several decades have brought us many treatments that target 
the functional capabilities of cancer. For example, bevacizumab blocks 
angiogenesis to starve the tumor and lomustine damages deoxyribonucleic acid 
(DNA) so that cells cannot replicate. Some oncologists have successfully treated 
patients with combinations of therapies to inhibit two or more arms of the 
functional capabilities simultaneously. Sadly, many patients achieve remission, 
but then later the cancer reemerges with resistance to the previously effective 
treatments. It was once thought that defeating cancer required targeting the 
functional capabilities. Certainly, survival rates have increased with new 
treatment strategies. Still, researchers do not fully understand how cancer 
reemerges and they have not discovered a successful pre-emptive treatment.   
 
Tumor-initiating cells 
The concept of cancer cell heterogeneity was described in the 1800s by 
Johannes Muller and Rudolf Carl Virchow shortly after they developed the 
specialty of microscopic pathology [88, 89]. Indeed, if all cancer cells within a 
tumor are identical, then any one cell would be able to repopulate the entire 
tumor. This is not the case. Cancer homogeneity was first disproven in 1962 
when doctors performed autografts on cancer patients with less than 35% 
success [90, 91]. Cancers are heterogeneous and only certain cells can 
repopulate the tumor [72, 85, 92-98]. Yet, traditional cancer therapies treat the 
cancer as if it the cell population is homogeneous [99]. Development of the 
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heterogeneous tumor is a complex process that begins with cells that specifically 
populate the tumor. Understanding these cells is the key to developing new 
classes of treatments. 
In 1875 a student of Virchow, Julius Cohnheim, proposed that cancer 
cells arise from initiating-type cells similar to what is observed in cellular 
propagation during embryogenesis [100]. This theory was revisited in the 1960s 
and 1970s, but fell short due to lack of technology [101-103]. Flow cytometry 
and immunocompromised mice became readily available in the 1990s. Finally, in 
1994 researchers successfully isolated initiating cells of acute myeloid leukemia 
[104]. This was followed by identification of tumor-initiating cells (TICs) in a 
variety of cancers [92, 105-116]. One hundred forty years later, it is accepted by 
almost all oncology researchers that cancers arise from cells that have 
mutations affording them tumor-initiating abilities. These TICs are a 
subpopulation of plastic cells within the tumor that have the ability to repopulate 
the tumor [105, 106, 117-122]. The two strongest theories of tumor-initiation and 
propagation are the hierarchical model and the stochastic model. They explain 
the evolution of a mature cancer from the first cell by adding an additional layer 
of sophistication to the model of clonal evolution. 
 
The hierarchical model of carcinogenesis 
In the hierarchical model of carcinogenesis, a stem cell or a progenitor 
cell follows the path of clonal evolution. The stem cell acquires tumor-initiating 
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properties after a series of mutations (Figure 2B). Thus, these cells are called 
cancer stem cells (CSCs) [123-125]. Like stem cells, they retain the ability to 
self-renew, enter quiescence, but they also lack boundaries on cell proliferation 
[96, 126]. Unlike embryonic stem cells, CSCs divide symmetrically and 
asymmetrically, yet retain the ability to divide indefinitely [127].  
A large magnitude of divisions is necessary to produce the first neoplastic 
cell. In adults, stem cells are relatively fewer in numbers and typically remain 
quiescent. Therefore, it would be mathematically improbable for stem cells to 
become CSCs in adult cancers [128]. In contrast, most of the common infant 
cancers originate from regenerative cells. Examples include neuroblastoma, 
leukemia, retinoblastoma, nephroblastoma, gonadal germ cell tumors, and 
hepatoblastoma [129, 130]. Therefore, the term “cancer stem cell” is more 
appropriate for infancy cancers. It is also used in some exceptions of adult 
cancers, such as teratomas or basal cell carcinomas, which also derive from 
stem or progenitor cells. 
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Figure 2. The hierarchical and stochastic models of carcinogenesis. (A) A 
normal stem cell has the capacity for self-renewal and may also give rise to 
progenitor cells. Progenitor cells give rise to differentiated cells. (B) If mutations 
cause normal stem cells or progenitor cells to become neoplastic, then they 
become cancer stem cells. These cells can populate a cancer. The cancer cells 
have the ability to dedifferentiate back into cancer stem cells. This is the 
hierarchical model. (C) In the stochastic model, differentiated cells go through a 
series of mutations and become neoplastic. The cancerous cell can then 
dedifferentiate into a tumor-initiating cell, with cancer stem cell properties. 
Adapted from Plaks et al. [131]  
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The stochastic model of carcinogenesis 
Cell plasticity is the central dogma of the stochastic model of 
carcinogenesis. Any cell from within the tumor is equally as likely to have been 
the first cancer cell (Figure 2C) [132-137]. For example, a normal differentiated 
cell may acquire a series of mutations in key cellular processes through clonal 
expansion. Eventually, mutations arise that allow dedifferentiation and this new 
phenotype activates progenitor or stem cell genes. This cell with the stem-like 
phenotype is a TIC. Tumor-initiating cells are similar to CSCs in that they have 
the ability to self-renew, enter a quiescence state, and divide indefinitely. Their 
plasticity allows them to phase between dedifferentiated and differentiated states 
[131, 133, 138-140].  
Adult and childhood cancers, such as osteosarcoma, most likely follow 
the stochastic model of carcinogenesis. Therefore, the term “tumor-initiating cell” 
will be used to describe repopulating cells with stem-like properties throughout 
this document. Other researchers may use TICs and CSCs interchangeably, but 
the current trend is to differentiate the two [141, 142]. To complicate matters 
further, it is possible that tumors could contain both CSCs and TICs within the 
heterogeneous population [143, 144]. Controversy aside, the important thing to 
note is that drugs targeting TICs would theoretically also target CSCs, and vice 
versa. Targeting TICs is believed to be the solution to cancer reemergence and 
treatment resistance [142]. 
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Properties of tumor-initiating cells 
A vast amount of information has been learned about TICs. They are 
resistant or can quickly become resistant to traditional radiation and 
chemotherapy treatments due to their slow replication rates and enhanced DNA 
repair mechanisms [142, 145-156]. Tumor-initiating cells heighten the tumor’s 
aggressiveness through angiogenesis, local invasion, and metastases [72, 105, 
157, 158]. One way they accomplish this is by activating stem cell genes that 
should otherwise be inactive in mature cells [157, 159, 160]. These genes can 
be used to identify or isolate TICs from the differentiated tumor cell population 
[84, 111, 161]. Expression levels of stem cell genes in cancer may also 
prognosticate the tumor [162-165]. Examples of stem-cell-specific genes include 
POU class 5 homeobox 1 (POU5F1 or OCT4), nanog homeobox (NANOG), and 
(Sex Determining Region Y)-Box 2 (SOX2) [166, 167]. TICs can also be 
identified by inherently increased cytoplasmic aldehyde dehydrogenase 
concentrations [168, 169]. 
As described earlier, TICs are plastic cells with the ability to phase 
between differentiated and dedifferentiated states [133, 139, 140]. Morphing into 
a dormant phase can be quite advantageous during times of stress [73-75, 146, 
170-172]. For example, chemotherapy that targets rapidly dividing cells would 
circumvent TICs hibernating in the G0 resting phase (G0) of the cell cycle. These 
unharmed cells could repopulate a heterogeneous tumor at a later time. Another 
way TICs avoid chemotherapy is through resistance. They have increased 
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expression of ABC transporters, which allows them to efflux toxic chemicals from 
the cell [173]. These cells are very efficient at DNA repair allowing them to heal 
after chemotherapy and radiation exposure [148, 174, 175]. Finally, it was 
initially thought that there was a very low proportion of TICs in tumors. However, 
this number can be quite high in some cancer types [73, 92, 120, 176]. Plus, the 
proportion of TICs can fluctuate as the properties of TICs evolve over time [142].  
 
Genes of interest 
 As one can imagine, there are a large number of genes involved in 
cancer and TICs. For the sake of conciseness, the canine osteosarcoma TIC 
genes of interest are briefly discussed next.  
 
NANOG  
 An important gene for TIC maintenance and identification is NANOG. In 
normal embryonic cells, NANOG is a transcription factor that is responsible for 
undifferentiated embryonic stem cell self-renewal. In other words, it prevents the 
stem cell from differentiating and losing its important properties. NANOG works 
with OCT4, SOX2, and Kruppel-Like Factor 4 in order to retain pluripotency 
[166, 177, 178]. Differentiated cells do not express NANOG and it has 
detrimental effects when expressed in neoplastic cells. It has been detected in 
most types of cancers and is associated with tumorigenicity, cell proliferation, 
tumor invasion, and therapy resistance [179-183]. Just as in embryogenesis, 
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NANOG requires cooperation with other genes in order to be oncogenic [184-
187]. 
 Perhaps the most interesting thing about NANOG is its genetic history 
and profile [188, 189]. There is a tandem duplication of NANOG in the human 
genome. The original copy is termed NANOG1, while the shorter duplication is 
NANOG2. NANOG2 does not seem to be functionally important. On the other 
hand, there is a functionally important complete duplication of NANOG1 on a 
separate chromosome, called NANOGP8. This copy lacks introns, which 
indicates that it is a retrotransposed gene. The NANOG1 and NANOGP8 
proteins differ by only one amino acid.  
 NANOG1 is transcriptionally silenced once it has completed its role in 
embryogenesis. The data shows that the NANOGP8 paralog is reactivated in 
most cancers [190-196]. There is only one version of NANOG identified in dogs. 
Most of the canine genome has been sequenced so there is still a possibility of 
NANOG paralogs to exist. This may be interpreted that activation of NANOG in 
human cancer may differ from activation of NANOG in canine cancer.  
 
OCT4 
 Just like NANOG, OCT4 is also an embryonic transcription factor [197]. It 
has additional abbreviations, such as OCT3 and OCT3/4, in some reports. 
OCT4 is the first gene to start the process of embryogenesis, establishing 
totipotency and pluripotency [198, 199]. OCT4 is found in rare adults cells, such 
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as basal cells within the skin [200]. In humans, OCT4 can be transcribed three 
ways, resulting in four protein isoforms [201-203]. The OCT4B transcript is 
generally exploited in cancer [204]. Pseudogenes of OCT4 have also been 
identified in cancer [205]. The canine ortholog of OCT4 has not been adequately 
evaluated, but is predicted to have one transcript. The canine genome sequence 
also has OCT4 pseudogenes (accession numbers XR_134596 and DQ131480). 
Expression of OCT4 been detected in numerous types of cancers [160, 166, 
180-183, 206-210]. In cancer, OCT4 is associated with initiation and 
aggressiveness of the tumor [209, 211, 212]. OCT4 is considered a therapeutic 
target due to its key role in carcinogenesis [200].  
 
p21 
 Cyclin-dependent kinase inhibitor 1A (p21) is a regulator of the cell cycle. 
Its major role is to stop progression of the cell cycle at G1 to keep the cell from 
going into the S phase. When the cell experiences DNA damage, tumor protein 
P53 (p53) induces p21, which then stops the cell cycle until repairs are complete 
[213]. In stem cells, p21 expression leads to cell quiescence [214-220]. This is 
an important ability for stem cells because it protects its valuable DNA [221]. 
Loss of p21 in stem cells results in a decreased number of stem cells or 
impaired function [222].  
In cancer, the role of p21 is quite controversial and sometimes 
contradictory [223]. Loss of or mutation of p21 may make tumors more 
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aggressive [224, 225]. It is believed that p21 may be induced independent of 
p53 in some cancers [155]. p21 has a dual role of preventing or encouraging 
apoptosis depending on the specific cancer and the conditions. Apoptosis is 
inhibited and cells proliferate when p21 is localized in the cytoplasm [223]. When 
CSCs or TICs overexpress p21 and enter quiescence, the outcome is cells that 
can avoid traditional therapies and later recur [144, 226-228]. This is clearly an 
advantage for the cancer, but a disadvantage for the patient. Some researchers 
believe that therapies targeting p21 will prevent cancer recurrence [118, 144]. 
Finally, p21 is a good marker to indicate quiescent TICs in experiments.  
 
p27 
 The cyclin-dependent kinase inhibitor 1B (p27) is another regulator of the 
cell cycle with a role in cancer [214, 215]. p27 is found in all normal differentiated 
cells and it plays a role in exiting quiescence. Loss of p27 is associated with 
cellular proliferation [213]. p27 messenger ribonucleic acid (mRNA) is expressed 
ubiquitously in cells while the p27 protein is regulated by degradation [229]. 
Quiescent cells have high levels of p27 protein [230]. Loss of p27 in stem cells 
results in proliferation of cells, but also loss of the stem cell phenotype [215]. An 
artificial gain of p27 results in increased numbers of stem cells, but also 
numerous tumors [231]. In cancer, loss of the p27 gene may result in benign 
hyperplasia or carcinogenesis progression [231-237].    
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Evidence for tumor-initiating cells in cancer 
The expression of genes such as NANOG and OCT4 can be relatively 
quantified with reverse transcription real-time polymerase chain reaction (RT-
qPCR). A subpopulation of cells with high expression of the stem cell gene, 
NANOG, is considered the TIC subpopulation, whereas the cells that do not 
express NANOG are the progenitor or differentiated subpopulation. The TIC 
subpopulation can also be verified with in vitro invasion assays or viability 
assays. The TIC subpopulation will be more invasive or more resistant, 
respectively, when compared to the differentiated tumor cells. The presence of 
TICs is ultimately supported when they grow after being injected into an 
immunodeficient mouse: a small number of TICs will produce a heterogeneous 
tumor at the injection site, whereas a much larger number of unsorted or 
negatively sorted cells are needed to grow the same tumor [142, 158, 238, 239].  
There are several limitations to conducting mouse xenograft experiments. 
First, TICs undergo harsh processing before being implanted [142]. It could take 
many hours or days before the cells are implanted. The phenotype of the cells 
could change while being cultured, depending on the plasticity of the cells. It is 
possible to inject TICs into the mouse but they fail to grow because the 
processing has killed them or driven them into quiescence. Next, important 
mouse proteins do not perfectly replicate proteins from other species. Growth 
factors, such as interleukin 3 and tumor necrosis factor, are not cross-species 
reactive [240, 241]. This could cause problems with tumor growth when 
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implanting cells from another species in mice. Lastly, the tumor 
microenvironment of the mouse may not adequately match the 
microenvironment from which the tumor derived [92]. It is quite common to inject 
a cancer of abdominal organ origin into the subcutis of the mouse. Researchers 
are trying to overcome these limitations with humanized mice [242], but this is 
not helpful when working with tumors cells from non-human species. Despite 
their limitations, immunodeficient mice are more commonly used over 
humanized mice for xenograft research because they are more affordable or 
because the humanized mouse required has not yet been created.  
 
Limitations of cell culture 
As mentioned above, a problem faced by researchers is the change in 
phenotype of cancer cells in culture. Cell culture is an incredible tool for 
understanding cancer. But, taking cells from a living organism and growing them 
on plastic with artificial nutrients and a loss of stroma changes the cell 
phenotype [243, 244]. This process selects for the most aggressive cancer cells 
in an expedited evolution process. This is not necessarily a bad outcome 
because the goal of cancer research is to find treatments for the most 
aggressive cells. But, this may select for cultured cells having a better 
adaptation at plasticity and thus increasing the true TIC proportion. The end 
result is a higher proportion of TICs in cultured cells versus the original tumor. It 
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is not uncommon to see differences between TICs samples directly from 
patients and TICs from cultured cancer cells [244].   
Some researchers have isolated TICs using antibodies specific to cell 
surface markers, such as prominin 1 (CD133) [119]. Sadly, cell surface markers 
are only reliable in a limited number of types of cancers and a limited number of 
species [245]. Solid tumors, especially sarcomas, lack reliable cell surface 
markers for TIC isolation [142]. To make matters worse, surface markers are 
dependent on the specific cell line in use. Variables such as passage number or 
culture conditions may change the surface proteins that are used to identify TICs 
[245]. In dogs, TIC surface marker research has been disappointing, especially 
in osteosarcoma [244, 246]. Sphere assays are also used by some laboratories 
to enrich for TICs, but this method has many flaws, such as an inability to 
differentiate between aggregated cells and true TIC spheres [247]. An 
alternative method to isolating TICs is to exploit their ability to resist 
chemotherapy. One group first treated the total cell population with epirubicin 
followed by a colony forming assay [248]. The result is an enriched TIC 
population, but there is no way to enrich for an epirubicin-susceptible population. 
In summary, it is possible for laboratories to use different methods for isolating 
TICs. This is acceptable as long as they use additional methods to validate that 
the cell fraction does indeed have properties of TICs [245]. 
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Tumor-initiating cells in dogs 
 The area of TIC research in canine cancers lags behind human cancer 
research. TICs from many types of cancers have been identified in vitro [244, 
246, 249]. But, only two types of canine TICs have been injected into mice: 
glioblastoma and mammary tumors [250-254]. Only one laboratory used 
negative controls for their canine TIC murine xenografts [252, 253]. Regardless, 
the in vitro work has produced useful information for future studies. As with 
human cancers, TICs from canine cancers are resistant to chemotherapy and 
radiation [255]. Unlike human cancers, TICs from canine cancers are not reliable 
identified with aldehyde dehydrogenase or dye efflux methods to isolate side 
populations [246]. As stated earlier, surface markers that work to isolate human 
cancer TICs rarely work with canine cancers [244, 246]. For example, CD44 
molecule (CD44) is expressed in almost every canine cancer cell making it 
impractical for isolating a TIC population [256]. Other markers are present in the 
solid tumor, but decrease once cultured in the laboratory [244]. Finally, NANOG 
and OCT4 have been identified in several types of canine cancers, including 
osteosarcoma [249, 257, 258]. These various reports give a broad but shallow 
summary of the current knowledge in this area of investigation. There is a clear 
need for more well-designed experiments in canine TIC research.  
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Tumor-initiating cells in osteosarcoma 
Compared to dogs, there are dozens of human osteosarcoma TIC reports 
published. Both aldehyde dehydrogenase and dye efflux methods, such as 
Hoechst, have been unreliable in sorting human osteosarcoma TICs [259-262]. 
Researchers have shown evidence that TICs can successfully grow in mice 
using the surface marker CD133 [263] or a combination of V-Kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog (CD117) and STRO-1 
[158] to isolate TICs. Human osteosarcoma TICs have upregulated embryologic 
genes such as NANOG, OCT4, and SOX2 [167, 259, 263-266]. They resist 
chemotherapy through upregulation of membrane transporters, such as ATP-
binding cassette, sub-family G (WHITE), member 2 (ABCG2) [158, 259, 264, 
267]. Human osteosarcoma TICs are known to have self-renewal properties, 
have increased DNA repair enzymes, and cause metastases [167]. Human 
osteosarcoma TICs with a loss of p27 have been shown to be more aggressive 
[268]. The next goal for researchers is to find treatments that reliable target 
these cells in hope of ending osteosarcoma metastasis and recurrence.  
 
Smoothened-Inhibition in Osteosarcoma 
 
The hedgehog pathway 
The hedgehog (HH) pathway has three ligands, with sonic hedgehog 
(SHH) being the most essential. Key embryologic events, such as midline 
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symmetry and dorsoventral organization, are mediated by SHH [269, 270]. This 
pathway is activated in cancers with detrimental results [271]. The HH pathway 
has a very interesting history in embryogenesis, cancer, and veterinary 
pathology. 
During normal embryologic development, SHH inhibits the membrane 
protein patched 1 (PTCH1) (Figure 3A) [272]. When PTCH1 is inhibited, 
smoothened (SMO) is freed to induce the glioma-associated oncogene family 
zinc finger transcription factors (GLI1, GLI2, GLI3). GLI activates genes needed 
for midline symmetry, neural development, limb development, facial 
morphogenesis, and hair development. Once these structures are generated 
and the genes are no longer needed, SHH is downregulated and PTCH1 is free 
to shut down the pathway by inhibiting SMO (Figure 3B) [271].  
There are four ways that cancers activate the SHH pathway [271]. The 
first category is ligand-independent activation of the HH pathway. This may arise 
by a loss-of-function mutation in PTCH1, aberrant activation of SMO, or aberrant 
activation of GLI (Figure 3C). The second category is ligand-dependent 
autocrine signaling. In other words, the cell overexpresses and secretes SHH, 
which in turn activates the cell. The third category is ligand-dependent paracrine 
signaling [273]. The secreted SHH activates adjacent cells in the supporting 
stroma. The fourth category is ligand-dependent reverse paracrine signaling, 
where stromal cells secrete SHH and activate the HH pathway in adjacent tumor 
cells. It is important to note that these differences play an important part in 
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treatment [271]. For instance, a SMO-inhibiting drug might not work on a cancer 
with aberrant GLI activation. 
 
 
Figure 3. The hedgehog pathway. (A) During normal embryologic 
development, SHH is secreted and inhibits PTCH1. This frees SMO to activate 
the GLI transcription factors for development. (B) Once complete, SHH is no 
longer expressed. The pathway becomes inactivated when PTCH1 inhibits 
SMO. (C) Cancer mutations in the HH pathway include: uncontrolled secretion of 
SHH, loss-of-function mutation in PTCH1, or aberrant activation of SMO. (D) 
SMO-inhibiting drugs can return the cell back to the inactivated state by 
inhibiting SMO. 
 
 
 
Regardless of how the HH pathway is activated in cancer, the result is 
similar. The GLI transcription factors activate genes for tumor-initiation, 
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proliferation, angiogenesis, apoptosis inhibition, metastases, and treatment 
resistance [271, 274-276]. The HH pathway also promotes stemness by 
regulating NANOG through a positive feedback loop [277, 278].  
Drugs that target the HH pathway have shown promising results in cancer 
research [279]. They function in a symbiotic relationship with other treatments: 
once the hedgehog pathway is inhibited then the cells become more vulnerable 
to traditional cytotoxic drugs. The HH pathway is a remarkable target because 
drugs that block the HH pathway ignore healthy stem cells; however, these 
drugs are obvious teratogens and should not be used during pregnancy. 
Upregulation of the HH pathway has been identified in a wide variety of cancers, 
making it a promising fundamental pathway for all carcinogenesis [280-289]. In 
addition, HH upregulation has been specifically identified in various cancer TICs 
[289-293]. The HH pathway has been shown to be upregulated in canine 
osteosarcoma [294].  
 
Smoothened-inhibitors 
SMO-inhibitors block the SHH pathway by inhibiting SMO (Figure 3D) 
[295]. This essentially shuts down the rest of the pathway. Cancer biologists 
have been evaluating several types of small molecules that target SMO as 
potential cancer treatments [280]. Two SMO-inhibitors, cyclopamine and 
vismodegib, are chosen for evaluation in this research.  
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Cyclopamine 
Cyclopamine is best known in veterinary medicine as the teratogen that 
causes cyclopia in fetuses of grazing animals [269, 296]. Much of what is known 
about the HH pathway was learned from cyclopamine toxicity. It is a steroidal 
jerveratrum alkaloid naturally found in corn lilies (Veratrum californicum) [297]. 
Cyclopamine very specifically targets and destroys stem cells by blocking the 
HH signaling pathway via SMO binding [298, 299]. In the pregnant animal, the 
result is lethal for the fetus with the dam remaining unaffected.  
Cyclopamine is easily accessed and inexpensive, making it a great 
chemical for in vitro studies. Unfortunately, it has poor bioavailability and causes 
unwanted side effects in mice [300, 301]. Cyclopamine treatment successfully 
transitioned drug resistant cell lines to become sensitive to chemotherapy in 
leukemia, prostate, and pancreatic cancers [276, 302-304]. In other cancers, 
cyclopamine inhibits self-renewal, slowed replication, enhanced apoptosis and 
targeted TICs [290, 293, 303-305]. Studies show a decrease in GLI expression 
in cells after cyclopamine treatment [305-307]. Cyclopamine is most effective 
when used in combination with other drugs [293]. Cyclopamine successfully 
inhibited human osteosarcoma cell lines [300] and canine transitional cell 
carcinoma cell lines [308]. It has not been evaluated on canine osteosarcoma.  
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Vismodegib 
Genentech developed Vismodegib as another drug that targets SMO, but 
it has better bioavailability and less side effects compared to cyclopamine [309]. 
It is the first Federal Drug Administration (FDA)-approved HH inhibiting drug, 
labeled for treatment of the hedgehog-predominant cancer basal cell carcinoma. 
Vismodegib treatment results in significant shrinkage of basal cell carcinomas 
[309]. Vismodegib has also shown promising results in other forms of cancer, 
like medulloblastoma and mesothelioma [310, 311]. Vismodegib specifically 
targets TICs in gastric cancer by making the cells less resistant to other 
chemotherapies [293]. Just this year, vismodegib has been shown to inhibit 
osteosarcoma metastasis in a mouse model [312]. Canine osteosarcoma has 
not been evaluated with vismodegib. As with cyclopamine, vismodegib also 
works symbiotically with other chemotherapies, and even other HH pathway 
inhibitors [312].  
 
HER2-Inhibition in Osteosarcoma 
 
A brief history of HER2 in cancer 
 Erb-B2 receptor tyrosine kinase 2 (HER2) is an epidermal growth factor. It 
is also called neu or ErbB2. The role of HER2 is to promote cellular proliferation 
and to oppose apoptosis by activating various signaling pathways [313]. The 
HER2 protein was discovered in the 1980’s from neuroblastomas of rats [314]. 
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Not long after, HER2 overexpression was revealed to be an important negative 
prognosticator identified in a fraction of all breast cancer biopsies [315]. In 1997, 
the first therapy targeting HER2 was approved by the FDA, called trastuzumab. 
The American Society of Clinical Oncology immediately updated their 
recommendations to check breast cancer biopsies for HER2 overexpression in 
order to target the HER2-positive fraction of patients appropriately [316]. This 
resulted in a ten-year survival improvement from 75% to 84% for HER2-positive 
breast cancer patients [317]. Since then, additional therapies have been created 
that target HER2.  
HER2 is expressed in low amounts in few healthy adult tissues, such as 
the breast and proliferating hematopoietic cells, whereas HER2 is generally 
widely overexpressed in HER2-positive cancers [318, 319]. Other cancers have 
been discovered to overexpress this protein, such as gastric, esophageal, 
ovarian, and uterine cancers [320-324]. HER2 has also been identified in human 
osteosarcoma [325]. In breast cancer, HER2 regulates TICs resulting in 
tumorigenesis, invasion, and radiation resistance [326, 327].   
 
HER2 in osteosarcoma 
In humans, the prognostication of HER2 in osteosarcoma is controversial. 
The majority of reports in osteosarcoma have shown that HER2 overexpression 
is associated with a poorer prognosis or metastasis [325, 328-334]. One study 
found patients with HER2-positive osteosarcoma have a better prognosis [335]. 
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Yet others claim that HER2 does not prognosticate osteosarcoma [336-340]. 
Perhaps the confusion in HER2 prognostication reports stems from the 
difference in HER2 expression and location between breast and bone tissues. 
Breast cancers that have multiple copies of the ERBB2 gene subsequently 
overexpress HER2. HER2 is located in the membrane of breast cancer resulting 
in intense membranous staining seen on immunohistochemistry [315]. In 
contrast, HER2 is generally diffuse throughout the cytoplasm in osteosarcoma 
[328, 332, 341]. Criteria outlined for breast cancer immunohistopathology would 
result in negative scoring of osteosarcoma biopsies. In addition, breast samples 
are evaluated from frozen sections, which have much more vivid staining 
compared to fixed samples used in retrospective studies [320]. Evidence 
suggests that HER2 does not need to be located in the membrane of 
osteosarcoma nor does the gene need to be duplicated in order to encourage 
carcinogenesis [342]. In other words, the mere presence of HER2 in 
osteosarcoma is enough evidence to warrant evaluation of HER2-targeting 
drugs. 
 
Lapatinib 
Trastuzumab is being used in human osteosarcoma studies [343], but it is 
a humanized monoclonal antibody. The future goal of this research is to use the 
dog in clinical trials. A human antibody would likely cause anaphylaxis in the dog 
with repeated dosing and would likely be less effective against canine HER2. 
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Instead, the drug lapatinib will be evaluated. Lapatinib was developed by 
GlaxoSmithKline as an alternative therapy for patients that become resistant to 
trastuzumab.  Trastuzumab targets HER2 from the extracellular matrix, whereas 
lapatinib enters the cell and targets HER2 from inside the cytoplasm (Figure 4). 
This makes lapatinib a more attractive therapy for osteosarcoma. Lapatinib has 
the affinity to block both HER2 and its homolog, HER1 [344]. Lapatinib is 
cytotoxic to HER2-positive cancers by preventing activation of the pathways 
downstream to HER2 [345]. Lapatinib has not yet been evaluated as a treatment 
for osteosarcoma.  
 
 
Figure 4. HER2 binding sites. The membrane receptor, HER2, can be targeted 
extracellularly (trastuzumab) or on the cytoplasmic side (lapatinib). Adapted from 
Vogel et al. [346] 
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Efficacy of lapatinib is evaluated by examining the expression of HER2 or 
by examining the expression of other genes downstream. V-Akt Murine 
Thymoma Viral Oncogene Homolog 1 (AKT1) is a member of the 
phosphatidylinositol 3-kinase pathway, an effector of HER2 mediation. AKT1 is 
involved with almost every category within the six hallmarks of cancer [347]. It is 
also associated with TIC self-renewal [348]. AKT1 will also be used for 
evaluation of HER2 inhibition by lapatinib for this study.  
HER2 has been identified in a range of canine cancers: mammary 
tumors, gastric carcinoma, astrocytoma, and melanoma [349-352]. HER2 is 
overexpressed in 86% of canine osteosarcoma cell lines and 40% of biopsies 
[353]. This suggests that lapatinib is ideal for evaluation as a treatment for 
canine osteosarcoma.   
 
Goals of Dissertation 
 
The goals of this dissertation are as follows: 
1. Develop a method to isolate TICs from osteosarcoma 
2. Determine the phenotypic differences in canine osteosarcoma TICs compared 
to differentiated cancer cells 
3. Evaluate two classes of drugs that specifically target TICs by taking 
advantage of their unique phenotypes in vitro and in vivo 
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MATERIALS AND METHODS 
 
Cell Lines and Management 
 
Cell lines 
Three immortalized canine osteosarcoma cell lines were used for the 
subsequent experiments: Abrams, NIH KOS-003 (MCKOS), and UWOS2. 
Abrams and UWOS2 were kindly provided by Dr. David Vail from the University 
of Wisconsin. The MCKOS cell line was a gift from the Comparative Oncology 
Trials Consortium at the National Institutes of Health National Cancer Institute.  
 
Cell culture 
Cells were cultured in 75 cm2 flasks containing R10 complete medium 
(R10) made of RPMI-1640 supplemented with 10% fetal bovine serum, 1% 
Penicillin/Streptomycin, and 0.2% Plasmocin™ (InvivoGen, California, USA). 
The cells were maintained at 37ºC in 5% carbon dioxide.  
 
TIC enrichment 
For TIC enrichment, osteosarcoma cells were grown as described above 
to 90% confluency. The medium was removed and replaced with R10 containing 
0.2 µg/ml of epirubicin (Areva, North Carolina, USA). The cells were incubated 
for 24 hours at 37ºC in 5% carbon dioxide. The medium containing the dead 
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differentiated cells was decanted and more dead cells were washed away with 
1x phosphate buffered saline (PBS). The remaining cells were trypsinized, 
centrifuged, and returned to a clean flask containing R10. The R10 was changed 
daily in flasks containing TICs until used in subsequent experiments. In two 
experiments where noted, TICs were enriched using R10 containing 2 µg/ml of 
epirubicin for 48 hours. 
 
Cell Culture Viability 
 
Calcein AM assay 
Cells were seeded onto black 96-well plates and allowed to attach to the 
bottom of the wells. Drugs were diluted in R10 and added to the wells in 
triplicates as follows: 0, 10, 20, 40, 60, and 80 µg/ml for epirubicin; 10, 30, 50, 
70, 90, 125, and 150 µM for cyclopamine (C4116, Sigma-Aldrich, Missouri, 
USA); 1, 5, 10, 50, 100, and 500 µM for vismodegib (kindly provided by 
Genentech for viability analyses, California, USA); and 5, 10, 20, 40, 60, 80, and 
100 µM for lapatinib (L-4804, LC Laboratories, Massachusetts, USA). Negative 
controls containing only R10 were used for epirubicin and vismodegib curves. 
The negative control for cyclopamine and lapatinib was R10 with 5% dimethyl 
sulfoxide (DMSO). The cells were incubated for 48 hours at 37ºC in 5% carbon 
dioxide. Three wells were treated with PBS containing 0.2% Triton X-100 for 15 
minutes to serve as a positive control for complete cell death. All wells were 
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decanted and washed with PBS. Next, 8µM Calcein AM (C0399, Life 
Technologies, California, USA) in PBS was added to all wells and incubated for 
30 minutes. The fluorescence was measured at 485 nm for excitation and 520 
nm for emission. The results were plotted on a curve and the equation of the 
curve was used to determine the lethal concentration (LC).  
 
Epirubicin viability assay 
Cells were seeded in flasks and grown to 70% confluency. The cells were 
trypsinized and resuspended in serum-free N2 medium, composed of 
Dulbecco’s Modified Eagle’s Medium (D8900-10X1L, Sigma-Aldrich, Missouri, 
USA) with 1% N-2 supplement (17502-048, ThermoFisher Scientific, California, 
USA), 1% Penicillin/Streptomycin, 0.2% Plasmocin™, 0.01% epidermal growth 
factor, and 0.01% fibroblast growth factor. The cells were added at a density of 3 
x 105 cells/ml using low attachment 6-well plates. Epirubicin was added to the 
treatment groups at a concentration of 2 µg/ml. The cells were incubated for 48 
hours at 37ºC in 5% carbon dioxide. The cells were differentially centrifuged. 
First, the cells were pelleted at 300 g for ten minutes. Next, the supernatant was 
removed and centrifuged at full speed for 5 minutes to collect any remaining 
cells. The two pellets were combined in 10µl of Trypsin-Versene® (Lonza, Basel, 
Switzerland). Viability was determined by counting the number of live and dead 
cells using the fluorescent acridine orange and propidium iodide (AO/PI) Assay 
(Nexcelom, Massachusetts, USA). Each cell line and variable was repeated in 
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triplicate. A repeated measures analysis-of-variance was used to determine if 
there was a statistical difference between the proportions of viable cells in the 
treated group. 
 
Viability assays for TICs 
TICs were prepared as described in the section above on TIC 
enrichment. The R10 was changed for three days. Next, the TICs were washed 
with 1x PBS and trypsinized. The TICs were counted using AO/PI solution in the 
Cellometer Auto 2000. The TICs were added to a 6-well low attachment plate 
suspended in N2 in triplicates at a density of 2 x 105 cells per well. Three wells 
were incubated with 15 µM and 50 µM vismodegib for 48 hours. Three wells 
were incubated in untreated N2 for negative controls. Three wells were 
incubated with 15 µM lapatinib for 24 hours, using equal volume DMSO for their 
three control wells. The cells were collected using differential centrifugation 
method described above. A repeated measures analysis-of-variance was used 
to determine if there was a statistical difference between the proportions of 
viable TICs in the treated group. 
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Immunocytochemistry and Immunohistochemistry 
 
Immunocytochemistry 
TICs were prepared as described in the section above on TIC 
enrichment. Unenriched cells and TICs were trypsinized and seeded onto 
separate chambered glass slides in R10. Once the cells attached to the glass, 
the medium was decanted and the slides were washed in 1x PBS and air dried. 
Antigen retrieval was conducted using Retrieval Buffer in a Decloaking Chamber 
(BioCare Medical, California, USA). The slides were washed with Tris buffer 
followed by an incubation with 3% hydrogen peroxide. Background Sniper was 
used as a blocking agent (BioCare Medical, California, USA). Anti-marker of 
proliferation Ki-67 (Ki-67) antibody was used at 1:100 dilution for one hour 
(275R-15, SP6; Cell Marque, California, USA). Anti-HER2/neu antibody was 
used at 1:2,000 dilution for one hour (sc-284; Santa Cruz, Texas, USA). The 
primary antibody was replaced with rabbit nonimmune sera for the negative 
controls (NP001, C-18, Dako, Glostrup, Denmark). The secondary antibody was 
applied for one hour (MACH2 anti-rabbit secondary antibody; BioCare Medical). 
Diaminobenzedine was used for antibody visualization, counterstained with 
hematoxylin. Finally, the slides were dehydrated through a series of ethanol and 
xylene and were coverslipped. A normal piece of canine bone was used as a 
tissue negative control. A piece of canine intestine with active cell division and a 
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HER2-positive human breast cancer tumor from a mouse xenograft were used 
as positive controls. 
 
Immunohistochemistry 
Immunohistochemistry was performed on formalin fixed paraffin 
embedded sections as described in the section on immunocytochemistry with 
the following addition. Before antigen retrieval, the slides were deparaffinized 
and rehydrated with a series of xylene and ethanol.  
 
Proportions of positive cells 
Multiple images of the slides were captured at 200x magnification 
(Microcast HD 3CCD 1080p Microscope Video Camera, Optronics, California, 
USA). The images were imported into ImageJ (National Institutes of Health, 
Maryland, USA). A script was designed to count the number of positive cells and 
the total number of cells (Figure 5). Images with large numbers of dead cells 
were counted manually. For Ki-67, the mitotic fraction was calculated by dividing 
the number of KI-67-positive cells by the total number of cells. The Wilcoxon 
rank sum test was used to determine if there was a statistical difference between 
the proportions of TIC-enriched cells versus the unenriched cells. 
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Figure 5. Scripts used for ImageJ analysis. Batch 1 counts only cells with 
DAB staining and Batch 2 counts the total number of cells. 
 
 
 
Evaluation of archived specimens from canine osteosarcoma patients 
The records of fifty dogs diagnosed with canine osteosarcoma from 2005-
2010 were abstracted for signalment, clinical findings, treatment, and date of 
death. Dogs that died from causes other than osteosarcoma were excluded. For 
each dog, hematoxylin and eosin (H&E) and HER2-stained slides were 
evaluated for osteosarcoma subtype, osteoid production, necrosis, HER2 
overexpression, mitotic score, and the average number of mitoses in five fields 
at 400x magnification. The Kaplan-Meier method was used to generate survival 
curves and the Cox proportional hazards model was used to evaluate these 
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variables. Dogs that were euthanized at diagnosis were not included in the 
analysis. 
 
Gene Expression 
 
Gene expression of canine osteosarcoma TICs 
TICs were prepared as described in the section above on TIC 
enrichment. The R10 medium was changed daily for seven days and each day 
one set of triplicates was frozen for ribonucleic acid (RNA) purification as 
described below. Triplicates of unenriched canine osteosarcoma cells and 
enriched TICs were compared over one week for the following genes: NANOG, 
OCT4, p21, and p27.  
 
Gene expression of canine osteosarcoma TICs following smoothened-inhibition 
TICs were prepared as described in the section above on TIC 
enrichment. Plated triplicates of TIC-enriched cells were treated with 25 µM of 
cyclopamine in R10 for 48 hours. Control TICs were incubated in R10 containing 
an equal volume of DMSO. Plated triplicates of TIC-enriched cells were also 
treated with 0 or 15 µM of vismodegib for 48 hours. Three sets of GLI primers 
were used to determine if the hedgehog pathway was downregulated by these 
smoothened-inhibiting drugs using RT-qPCR as described below.  
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Gene expression of canine osteosarcoma TICs following HER2-inhibition 
TICs were prepared as described in the section above on TIC 
enrichment. Triplicates of plated TIC-enriched cells were treated with 15 µM of 
cyclopamine in R10 medium for 48 hours. Control TICs were incubated in R10 
containing an equal volume of DMSO. AKT1 and HER2 primers were evaluated 
for suppression in the treated samples versus the untreated samples, as 
described below.  
 
Relative RT-qPCR 
For the experiments listed above, RNA was purified according to the 
manufacturer’s instructions (Isolate II RNA Mini Kit #BIO-52072, BioLine, 
London, UK). Equal amounts of RNA was used to generate cDNA (iScript™ 
Reverse Transcription Supermix for RT-qPCR #1708841, BioRad, California, 
USA). Relative RT-qPCR was performed with biological and technical triplicates 
(SsoAdvanced™ Universal SYBR® Green Supermix #1725271 and CFX 
Connect™ Real-Time PCR Detection System #1855201, BioRad, California, 
USA). Two normalization genes were used: GAPDH and RPS19. All of the 
primers are listed in Table 1. Primers for GLI2 were created using GenBank 
sequence XM_003432472.2. Primers for GLI3 were created using GenBank 
sequence XM_005630926.1. The cycling conditions were 30 seconds at 95ºC, 
followed by 40 cycles of 10 seconds at 95ºC and 5 seconds at 62ºC. The Delta-
Delta-CT method was used to determine the relative fold change between 
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unenriched and TIC-enriched cells. The standard deviation was calculated 
based on the CT values and converted with the fold change analysis. 
Significance was determined by calculating a Student’s t-test on the difference 
between CT values of the normalizing gene and gene of interest and between 
the control and target groups. 
 
Table 2. Canine specific primer pairs used in RT-qPCR. 
Primer Sequence 5’ to 3’ 
Amplicon 
Size Citation 
GAPDH Forward TATCAGTTGTGGATCTGACCTG 172 bp [354] 
GAPDH Reverse GCGTCGAAGGTGGAAGAGT 
RPS19 Forward CCTTCCTCAAAAA/GTCTGGG 95 bp [355] 
RPS19 Reverse GTTCTCATCGTAGGGAGCAAG 
NANOG Forward CCTGCATCCTTGCCAATGTC 98 bp [354] 
NANOG Reverse TCCGGGCTGTCCTGAGTAAG 
OCT4 Forward GAGTGAGAGGCAACCTGGAG 274 bp [356] 
OCT4 Reverse GTGAAGTGAGGGCTCCCATA 
p21 Forward ACCTCTCAGGGCCGAAAAC 88 bp [357] 
p21 Reverse TAGGGCTTCCTCTTGGAGAA 
p27 Forward CAGAGGACACACACTTGTAGA 124 bp [357] 
P27 Reverse TCTTTTGTTTTGAGGAGAGGAA 
GLI1 Forward ACCTCCATGATAGGCAGTGG 217 bp [253] 
GLI1 Reverse ACTCACCCCATGGTTCAGAG 
GLI2 Forward GGTGGTACACATGCGCCGA  107 bp N/A 
GLI2 Reverse ACCGCAGGTGTGTCTTCAGG 
GLI3 Forward CCACGGGGCCAGCAGGAACA 128 bp N/A 
GLI3 Reverse TCCCGCGTGCAACCTTCCCA 
AKT1 Forward CACCGTGTGACCATGAATGAG 83 bp [358] 
AKT1 Reverse TTCTCCTTGACCAGGATCACC 
HER2 Forward AGCAGAGAGCCAGCCCTGTGACATC 137 bp [359] 
HER2 Reverse GCAGCCTCCGCATAGTGTACTTCCG 
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Murine Studies 
 
Institutional Animal Care and Use Committee approval 
All animal studies were approved by the Texas A&M University 
Institutional Animal Care and Use Committee. The Animal Use Protocol 
numbers for the following studies were IACUC 2014-0079 and IACUC 2014-
0329. Both Abrams and MCKOS cell lines were tested for murine pathogens 
before starting the following studies (Mouse Essential Panel. Charles River, 
Massachusetts, USA; MycoAlert™ PLUS Mycoplasma Detection Kit, Lonza, 
Basel, Switzerland). 
 
Limiting dilution assay - Abrams 
The TICs were enriched using the more aggressive method of 2 µg/ml of 
epirubicin for 48 hours. Unenriched cells and TIC-enriched cells at 
concentrations of 100, 1,000, and 10,000 cells were subcutaneously injected 
suspended in Matrigel® (#356230, Corning®, New York, USA). Eight athymic 
nude mice (Strain 490, Charles River, Massachusetts, USA) were used for each 
group, with some mice receiving bilateral injections. Eight control mice were 
injected with Matrigel only to serve as negative controls. The tumor size and 
weight of each mouse was recorded twice per week. The tumors were allowed 
to form and grow for seven weeks. The mice in the 100 unenriched cells group 
and all three TIC groups were euthanized at seven weeks. The Matrigel control 
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mice were euthanized at four weeks. The remaining mice were used in 
subsequent studies. The subcutaneous tissues from all mice were processed to 
make routine H&E microscope slides and were evaluated for tumor growth.  
 
Oral chemotherapy 
The chemicals were purchased in a powdered form and suspended in a 
vehicle as follows. For vismodegib (V-4050, LC Laboratories, Massachusetts, 
USA), the drug was suspended in 0.5% methylcellulose with 0.2% Tween 80. 
For lapatinib, the drug was suspended in 0.1% Tween 80. A mixture of the 
vehicle for each treatment was prepared without the drug additive to serve as a 
placebo for the control mice.  
Twelve mice with subcutaneous tumors from the Abrams limiting dilution 
assay above were treated with oral chemotherapy once the tumor reached a 
volume 0.3-0.6 cm3. Three mice that received injections of 1,000 unenriched 
Abrams cells were gavaged with vismodegib at 75 mg/kg twice daily for two 
weeks. Three additional mice were gavaged with an equal volume of vehicle to 
serve as controls. Three mice that received injections of 10,000 unenriched 
Abrams cells were gavaged with lapatinib at 75 mg/kg daily for three weeks. 
Three additional mice were gavaged with an equal volume of vehicle. The tumor 
size and weight of each mouse was recorded twice per week. Any mouse with a 
tumor exceeding 1 cm3 was immediately euthanized. All mice were euthanized 
at the end of the treatment period. Sections of the tumor were flash frozen in 
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liquid nitrogen and a section of each tumor was saved for histology. The lungs 
were also saved for histology. 
 
Limiting dilution assay - MCKOS 
The MCKOS TICs were enriched using the gentle procedure described 
earlier, using 0.2 µg/ml of epirubicin for 24 hours. The TICs were trypsinized and 
placed in a clean flask with fresh R10. The R10 was changed daily for one week 
and used for injection once the TICs began replicating. Unenriched cells and 
TIC-enriched MCKOS cells suspended in Matrigel were bilaterally injected 
subcutaneously in groups of four athymic nude mice. The concentrations used 
were 100, 1,000, and 10,000 cells. Four control mice were injected with only 
Matrigel to serve as negative controls. The cells were allowed to grow for four 
weeks. Mouse weight and tumor size was recorded twice weekly. The mice were 
necropsied at the end of the study. Sections of each tumor and the lungs were 
saved for routine H&E histology. 
 
Pulmonary metastasis model for vismodegib evaluation 
One million unenriched cells were retro-orbitally injected into eight 
athymic nude mice. One day later, four mice began vismodegib treatment at 75 
mg/kg twice daily for up to three weeks. The vismodegib was suspended in corn 
oil for this treatment study. The other four mice were gavaged with an equal 
volume of corn oil to serve as controls. Exophthalmos and more than 20% 
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weight loss were used as endpoints for this study. The mice were necropsied 
and the lungs were saved for routine H&E histology.  
The lungs were sectioned for microscope slides so that five non-serial 
sections of lungs were available for evaluation from each mouse. The number of 
metastatic MCKOS colonies was counted in each of the five sections. The slide 
with the highest number of colonies from each mouse was selected for imaging. 
Microscopic images of the lungs were taken at 100x magnification. The area of 
each pulmonary metastasis was measured using ImageJ. The formalin fixed 
paraffin embedded blocks were then used for quantitative DNA analysis. 
 
Quantitative DNA analysis of lungs 
The formalin fixed paraffin embedded blocks from the mice of the 
vismodegib pulmonary metastases treatment study were evaluated for the 
quantity of canine DNA in the lungs. Lungs from mice that received only Matrigel 
injections were used as negative controls. DNA was purified from ten 5 µm wide 
sections of lungs according to the manufacturer’s instruction (QIAamp DNA 
FFPE Tissue Kit, Qiagen, Limburg, Netherlands). Each sample was run in 
triplicate using 45 ng of template per well (SsoAdvanced™ Universal SYBR® 
Green Supermix #1725271 and CFX Connect™ Real-Time PCR Detection 
System #1855201, BioRad, California, USA). Canine specific primers that target 
a short interspersed element, or SINE, were used to target canine DNA within 
the mouse lung DNA samples (forward: 5’-AGGGCGCGATCCTGGAGAC-3’, 
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reverse: 5’- AGACACAGGCAGAGGGAGAA-3’) [360]. A standard curve was 
created by mixing known quantities of DNA from a canine papilloma biopsy with 
known quantities of DNA from a mouse lung, ranging from 45 fg to 45 ng per 
reaction. The cycling conditions were three minutes at 98ºC, followed by 40 
cycles of 15 seconds at 98ºC, 30 seconds at 55ºC, 20 seconds at 60ºC, and 15 
seconds at 72ºC.  
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RESULTS AND INTERPRETATION 
 
Tumor-Initiating Cells 
 
Determination of the lethal concentration of epirubicin 
A Calcein AM assay was used to determine the lethal concentration of 
epirubicin. The 95%, 75% and 50% lethal concentrations were estimated from 
the equation of the logarithmic curve (Figure 6: LC95, LC75, and LC50). The LC50 
cannot be reliable from this data set because the concentrations of epirubicin 
were not low enough. Based on these results, concentrations at 2 μg/ml or less 
were used for subsequent experiments.  
 
Tumor-initiating cell viability assay 
An AO/PI viability assay was performed to determine the proportion of 
cells killed by epirubicin in stressed cell culture conditions. Approximately 22% of 
unenriched cells died once suspended in serum-free medium (Figure 7). An 
additional 27% of cells were killed when 2 μg/ml epirubicin was added to the 
medium, for a final viability of 49%. This difference of means was statistically 
significant (0.78 for untreated cells, 0.49 for treated cells, p = 0.004). Cells in 
both the untreated wells and the treated wells gathered similar to what is seen in 
sarcosphere culture, but in this case it was clearly clumping. A higher number of 
cells was predicted to die in the treatment group. This may indicate that the 
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harsh conditions drove cells to change phenotypes to increase TIC proportion. 
Alternatively, the cells that were killed early on in the experiment became lysed 
and undetectable, artificially lowering the dead fraction. 
 
 
Figure 6. Percent survival of canine osteosarcoma cell lines after 48 hours 
of epirubicin treatment. The curves shown are the proportions of viable cells 
after treatments of various concentrations of epirubicin. The logarithmic curve 
was used to calculate the 95%, 75%, and 50% lethal concentrations. The lethal 
concentrations are summarized in the inset. The associated R2 values of the 
curves are also listed. * The LC50 is not accurately predicted because very low 
concentrations of epirubicin were not used and these values should be 
interpreted with care. 
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Figure 7. Percent viability of canine osteosarcoma cells after 48 hours of 
epirubicin treatment in stressful conditions. The experiments were carried 
out in triplicates as represented by the clusters on the graph. The wide bar 
depicts the mean and the shorter bars are standard error of the mean. The 
mean proportion viable differed significantly for the treatment group (0.78 for 
untreated cells, 0.49 for treated cells, p = 0.004). 
 
 
 
Properties of tumor-initiating cells in culture 
Numerous observations were made regarding TIC morphology and 
behavior changes during the proceeding experiments. Cells from the TIC-
enriched population were generally much larger than the differentiated 
osteosarcoma cells, with some multinucleated cells (Figure 8). The TICs had 
more membrane projections and the nuclei were more distinct. When enriched 
with 2 μg/ml of epirubicin, the cells did not repopulate the flasks for eight weeks. 
At eight weeks, the cells began replicating and the flask reached confluency in 
another week. When the more gentle enrichment of 0.2 μg/ml was used, the 
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cells remained dormant for a much shorter period of time. The first cell 
replication was observed on the fifth day. These observations indicate a 
quiescent cell population instigated by the harshness of the environment. 
 
 
Figure 8. Abrams and MCKOS culture. (A) Unenriched Abrams cells and (C) 
unenriched MCKOS cells displayed typical osteosarcoma morphology in culture. 
(B) Abrams TICs and (D) MCKOS TICs had pronounced nuclei and 
membranous projections. 400x magnification. 
 
 
Ki-67 immunocytochemistry for evaluation of cell growth fraction 
In order to verify that the TICs were quiescent, the cells were labeled with 
Ki-67 (Figure 9). This antibody selects for cells that are actively within the cell 
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cycle, and neglect to adhere to cells in G0. For unenriched Abrams, 53.5% of the 
cells were in G0 (Figure 10). For TIC-enriched Abrams, 93.8% of the cells were 
in G0. For unenriched MCKOS, 56.3% of the cells were in G0. For TIC-enriched 
MCKOS, 96.8% of the cells were in G0. These results indicate that the majority 
of TICs enter quiescence with exposure to epirubicin. 
 
 
 
Figure 9. Abrams and MCKOS labeled with Ki-67. Actively dividing cells are 
labeled with Ki-67. The proportion was higher in (A) unenriched Abrams and (C) 
unenriched MCKOS compared to their TIC-enriched counterparts. (B) Abrams 
TICs and (D) MCKOS TICs had few labeled cells. 200x magnification. 
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Figure 10. Cell growth fraction. The cells labeled with Ki-76 were counted and 
the unenriched cells had considerably higher growth fractions. The non-dividing 
proportions were as follows: 53.5% for unenriched Abrams, 93.8% for Abrams 
TICs, 56.3% for unenriched MCKOS, and 96.8% for MCKOS TICs. 
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Tumor-initiating cell gene expression 
To validate that the enriched population was composed of TICs, RT-
qPCR was performed for the stem cell specific genes, NANOG and OCT4. 
Enriched cells were collected for one week post-epirubicin treatment. The 
relative fold change is presented in Figure 11. Both cell lines had an increased 
expression in NANOG in the TIC-enriched population compared to the untreated 
cells, which had no detectable NANOG. OCT4 expression was not as expected, 
with only a small upregulation at the beginning of the week. This may be a 
product of the difficulty in designing OCT4 primers that disregard the 
pseudogene. Regardless, the presence of NANOG in the TIC population is 
enough evidence to support stemness. Next, the cells were evaluated for 
quiescence through expression of p21 and p27. The level of p21 was increased 
at the beginning of the week when the cells were not dividing and the level of 
p27 dropped as cells began repopulating. Thus, canine osteosarcoma cells 
treated with epirubicin successfully produced a quiescent TIC-enriched 
subpopulation. 
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Figure 11. Gene expression in TICs over one week. (A) NANOG levels are 
high in the TIC population, but once the cells begin replicating it was diluted out. 
(B) OCT4 expression was lower than expected with only a small increase at the 
beginning of the week. (C) The levels of p21 were increased when the cells were 
not dividing, as expected. (D) On day 5, the level of p27 dropped when the cells 
began dividing.  
 
 
Demonstration of quiescence in a murine xenograft model 
Abrams TICs were ectopically transplanted into athymic nude mice to 
evaluate quiescence in vivo. Compared to mock injections, viable cells were 
identified in the tissue site six weeks post injection (Figure 12). This indicates 
that TICs remain quiescent despite a change in microenvironment and that TICs 
exiting G0 must be used to determine if TICs can repopulated a tumor in vivo. 
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Figure 12. H&E sections of Matrigel. (A) The control mice were injected with 
only Matrigel. Sections from these mice all had similar features of fibrocytes and 
fatty infiltration. (B) Most of the mice injected with TICs had numerous cells with 
large cytoplasm throughout the Matrigel. Many cells were binucleated. 200x 
magnification. 
 
 
 
Limiting dilution assay in a murine xenograft model 
In order to determine the lowest number of cells needed to repopulate the 
tumor, a limiting assay was performed using athymic nude mice. MCKOS TICs 
recently exiting G0 were used. It was expected that tumors would grow in the 
higher groups of unenriched cells, but not the injections of 100 cells. The tumors 
were confirmed microscopically (Figure 13). Regrettably, tumors grew in 
quantities of 10,000, 1,000, and 100 cells for the unenriched populations. Some 
of the Matrigel pellets were unable to be recovered. The results from pellets that 
were recovered are summarized in Table 3. This could indicate that the TIC 
subpopulation was not properly identified in these cells. Or, more likely, it means 
that the MCKOS cell line has a high population of plastic cells allowing for 
increased numbers of TICs in the new microenvironment. 
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Figure 13. H&E sections of MCKOS tumors from murine xenografts. (A) 
Unsorted MCKOS cells and (B) MCKOS TIC derived cells invading Matrigel. 
200x magnification. 
 
 
 
Table 3. Limiting dilution assay of MCKOS cells in athymic nude mice. 
Number of Cells Unenriched TICs Matrigel 
10,000 8/8 8/8 0/8 
1,000 7/7 8/8  
100 8/8 4/4  
 
 
 
Smoothened-Inhibition 
 
Determination of the lethal concentration of cyclopamine and vismodegib 
A Calcein AM assay was performed for both cyclopamine and 
vismodegib. The assay did not give a correlative lethal dose curve because it 
appears that these drugs do not kill canine osteosarcoma cells in a dose-
dependent manner. An AO/PI viability assay was performed on Abrams and 
MCKOS TICs using vismodegib (Figure 14). After 48 hours, there was no 
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difference in reduction of TICs treated with vismodegib. This means that 
smoothened-inhibition does not appear to kill canine osteosarcoma cells. This is 
not a dire situation because these drugs may have a cytostatic effect on tumor 
cells through inhibition of invasion or TIC-plasticity.  
 
 
Figure 14. Vismodegib viability assay. The experiments were carried out in 
triplicates as represented by the clusters on the graph. The wide bar depicts the 
mean and the shorter bars are standard error of the mean. The mean proportion 
viable did not significantly differ for the treatment groups indicating that 
vismodegib did not kill cells off TICs (p = 0.3 for 15 µM; p = 0.1 for 50 µM).  
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Gene expression after smoothened-inhibition 
Expression levels of the GLI transcription factors was determined in order 
to verify that smoothened-inhibiting drugs properly target the HH pathway in 
canine osteosarcoma. Control TICs were compared to treated TICs. 
Cyclopamine had a much better effect on the HH pathway compared to 
vismodegib, as shown by the larger decrease in GLI expression (Figure 15). 
This indicates that cyclopamine and vismodegib do target the HH pathway of 
canine osteosarcoma TICs.  
 
 
Figure 15. Smoothened-inhibition of GLI. TICs were treated with cyclopamine 
(A) and vismodegib (B) to evaluate if the HH pathway was inhibited in canine 
osteosarcoma. The bars represent the standard deviation.  
 
 
 
Vismodegib treatment for solid tumors 
Next, the efficacy of vismodegib was evaluated for treatment of solid 
tumors in mice. Tumor size was measured over two weeks with no difference 
between the treated and untreated groups of mice in size (Figure 16) or percent 
growth (Figure 17). Frozen tissues for one treated mouse was available. 
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Compared to three untreated mice, the treated mouse had inhibition of the HH 
pathway, demonstrated by decreased GLI (Figure 18). These results indicate 
that vismodegib is probably not adequate for treating primary tumors of clinical 
patients. Yet, the inhibition of the HH pathway supports that it might work better 
for preventing or inhibiting micrometastases.  
 
 
Figure 16. Tumor measurements from mice treated with vismodegib. 
Tumors were measured for two weeks and vismodegib did not slow the growth 
of canine osteosarcoma tumors. 
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Figure 17. Percent change in tumor growth from mice treated with 
vismodegib. Tumors were measured for two weeks and vismodegib did not 
slow the growth of canine osteosarcoma tumors. 
 
 
 
 
Figure 18. Vismodegib inhibition of GLI. One mouse from the treated group 
was available for GLI expression analysis. GLI1 showed the most inhibition in 
vivo when compared to the untreated mice. 
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Vismodegib treatment for pulmonary metastasis 
To establish if vismodegib prevented pulmonary metastasis, unenriched 
cells were intravenously injected into athymic nude mice to represent 
metastases. MCKOS has a high subpopulation of TICs, which allows for seeding 
and invasion of the lungs. Vismodegib or placebo treatments were started the 
following day and the lungs were evaluated for metastases upon completion of 
the study. One mouse from each group had to be euthanized early due to 
aspiration pneumonia. Of the remaining six mice, two control mice and one 
treated mouse had to be euthanized early due to exophthalmos (Table 4).  
 
Table 4. Number of days until mice were euthanized. 
Mouse Vehicle Vismodegib 
D 20 days 20 days 
E 15 days 15 days 
F 15 days 20 days 
  
 
 
The results were recorded two novel ways and analyzed three ways. 
First, digital measurements were taken of the lungs to determine metastatic area 
(Figure 19). Next, the digital measurements were reported as a portion of lung 
area to report the total tumor burden (Figure 20). Finally, quantitative real-time 
polymerase chain reaction (qPCR) was used to calculate the amount of canine 
DNA within the mouse DNA from the lungs (Figure 21). All three methods gave 
similar results with one untreated mouse having a very high tumor burden, and 
all three treated mice having a low tumor burden. This is just a small pilot study, 
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but these data support the use of vismodegib as an adjuvant therapy for canine 
osteosarcoma to prevent the growth and progression of micrometastases after 
primary tumor removal.  
 
 
Figure 19. Area of pulmonary metastases. The total area of tumor cells was 
measured for each mouse. The bars represent the mean area and the line graph 
represents the median for each mouse. 
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Figure 20. Tumor burden on lungs. The percent tumor burden was calculated 
by dividing the area of mouse tumor by the total area of lung for each mouse.  
 
 
 
 
Figure 21. Percent of canine DNA in murine lungs. DNA from the lungs of 
each mouse was purified. Quantitative DNA analysis revealed similar results to 
the image analysis. The bars represent the standard deviation.  
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HER2-Inhibition 
 
HER2 in spontaneous canine osteosarcoma 
To determine if HER2 is prognostic in a canine osteosarcoma population, 
47 cases were evaluated. The ages of the dogs at diagnosis ranged from one to 
17 years. The average age of diagnosis was 7.4 years. Some dogs were 
euthanized at diagnosis and were not included in the survival analysis. The 
shortest survival time was 21 days. The dog with the longest survival was 2,533 
days. The median survival time as determined by Kaplan-Meier analysis was 
159 days. Seventeen different breeds of dogs and six mixed breeds were 
included in the population. Five purebred breeds were overrepresented: nine 
rottweilers, nine Labrador retrievers, four golden retrievers, three greyhounds, 
and three German shepherd dogs. Rottweilers and retrievers had a poorer 
survival time than the other breeds of dogs within this population (p = 0.0005 
and p = 0.07, respectively). The population was roughly half male (48.9%) and 
half female (51.1%). Six dogs were intact, whereas 42 dogs were surgically 
sterilized. Dogs that received surgery had a better survival than dogs that did not 
(p = 0.001). 
The seven subtypes observed in this population are represented in Figure 
22 (A-G). The HER2 labeling was diffuse and cytoplasmic, as observed in 
human samples (Figure 22H-I). Tumors were considered positive if the staining 
intensity was stronger than what is seen in healthy bone. Within this population 
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85.1% of the canine osteosarcomas overexpressed HER2. Survival was 
compared to HER2 overexpression, osteosarcoma subtype, mitotic rate, and 
other variables. HER2 overexpression did not prognosticate survival (Figure 23). 
The population was not large enough to determine if histologic subtype was 
associated with survival or HER2 overexpression. Other histologic features did 
not predict survival nor HER2 overexpression within this population. A larger 
sample size may have powered this study better in order to determine more 
predictive variables. Even though HER2 overexpression was not a good 
prognostic indicator in canine osteosarcoma, the mere presence of HER2 in 
canine osteosarcoma supports investigation of drugs that target this protein. 
 
HER2 in canine osteosarcoma cell lines 
Next, HER2 was identified in Abrams and MCKOS cell lines using 
immunocytochemistry (Figure 24). Both unenriched cells and TIC-enriched cells 
had strong and uniform HER2 labelling. Additional cells lines should be 
evaluated to determine if some canine osteosarcomas exhibit a difference in 
HER2 expression in the TIC subpopulation.   
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Figure 22. Spontaneous canine osteosarcoma histology. Images of H&E 
stained tumors represent the different osteosarcoma subtypes identified in this 
population. They consist of (A) osteoblastic, (B) fibroblastic, (C) chrondroblastic, 
(D) giant cell, (E) telangiectatic, (F) sclerotic, and (G) anaplastic. An 
osteosarcoma with normal (H) and overexpressed (I) HER2 labeling 
demonstrate the difference in staining intensity between groups. 200x 
magnification. 
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Figure 23. Kaplan-Meier survival curves. HER2 overexpression in 
spontaneous canine osteosarcomas (red) was not prognostic when compared to 
osteosarcomas with staining intensity similar to bone (blue). 
 
 
 
 71 
 
 
Figure 24. HER2 immunocytochemistry. (A) Unenriched Abrams cells, (B) 
TIC-enriched Abrams, (C) unenriched MCKOS, and (D) TIC-enriched MCKOS 
all exhibit strong HER2 labeling. 200x magnification. 
 
 
Determination of the lethal concentration of lapatinib 
A Calcein AM assay was used to determine the lethal concentration of 
lapatinib. The 95%, 75% and 50% lethal concentrations were estimated from the 
equation of the logarithmic curve (Figure 25: LC95, LC75, and LC50). These results 
are consistent with reports from other laboratories for other human cancer cell 
lines. An AO/PI viability assay was performed on Abrams and MCKOS TICs 
using lapatinib (Figure 26). After 24 hours, there was a significant reduction in 
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TICs (0.63 for DMSO-treated control TICs, 0.41 for lapatinib-treated TICs, p = 
0.04). This indicates that lapatinib targets HER2 in canine osteosarcoma TICs 
with lethal consequences. 
 
 
Figure 25. Percent survival of canine osteosarcoma cell lines after 48 
hours of lapatinib treatment. The curves shown are the proportions of viable 
cells after treatments of various concentrations of lapatinib. The logarithmic 
curve was used to calculate the 95%, 75%, and 50% lethal concentrations. The 
lethal concentrations are summarized in the inset. The associated R2 values of 
the curves are also listed. 
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Figure 26. Lapatinib viability assay. The experiments were carried out in 
triplicates as represented by the clusters on the graph. The wide bar depicts the 
mean and the shorter bars are standard error of the mean. The mean proportion 
viable differed significantly for the treatment group (0.63 for DMSO-treated 
control TICs, 0.41 for lapatinib-treated TICs, p = 0.04). 
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Gene expression following lapatinib treatment 
Canine osteosarcoma cells were evaluated in vitro to establish if lapatinib 
treatment inhibits HER2 (Figure 27) and its downstream mediator, AKT1 (Figure 
28). First, unenriched cells were evaluated at three concentrations: 7.5, 15, and 
22.5 μm. Both genes were downregulated with almost all concentrations. Next, 
TICs from both cell lines were evaluated after lapatinib treatment. Both AKT1 
and HER2 were downregulated in the treated TICs (Figure 29). These results 
indicate that lapatinib targets HER2 in canine osteosarcoma differentiated cells 
and TICs. 
 
 
Figure 27. HER2 expression after lapatinib treatment. HER2 was reduced in 
both Abrams and MCKOS cell lines at higher concentrations of lapatinib. The 
bars represent the standard deviation. 
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Figure 28. AKT1 expression after lapatinib treatment. AKT1 was reduced in 
both Abrams and MCKOS cell lines at all concentrations of lapatinib. The bars 
represent the standard deviation. 
 
 
 
 
Figure 29. AKT1 and HER2 expression in TICs treated with lapatinib. AKT1 
and HER2 were both downregulated in TICs from Abrams and MCKOS. The 
bars represent the standard deviation. 
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Lapatinib treatment for solid tumors 
Finally, to determine the efficacy of lapatinib, mice with solid Abrams 
tumors were treated. Half of the tumors from treated mice had slower growth 
compared to the untreated mice receiving vehicle only (Figure 30 and 31). The 
tumors from the treated group had depressions indicating necrosis and these 
findings corresponded with the histologic findings (Figure 32A-B). Four out of 
four tumors from treated mice had necrosis whereas only two of the four control 
tumors did. HER2 was downregulated in the tumors from the treated mice, but 
surprisingly, AKT1 was not (Figure 32C). The mitotic rate was 3% higher in the 
treated tumors (Figure 32D). These results are inconclusive for a pilot study, but 
supports investigating lapatinib with larger samples and in other species.  
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Figure 30. Tumor measurements from mice treated with lapatinib. Tumors 
were measured over 15 days with approximately half of the tumors slowed with 
lapatinib treatment. 
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Figure 31. Percent change in tumor growth from mice treated with 
lapatinib. Tumors were measured for 15 days and the change from the first day 
was plotted with approximately half of the tumors slowed with lapatinib 
treatment. 
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Figure 32. Mice treated with lapatinib. (A) Untreated mice had plump tumors, 
whereas lapatinib-treated mice (B) had bumpy tumors with areas of collapse 
from necrosis. (C) HER2 expression was slightly decreased in treated mice, but 
AKT1 was not. (D) The proliferation rate was determined using Ki-67 
immunocytochemistry. The tumors from the lapatinib treated mice had an 
increase of 3%. 
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CONCLUSION 
 
Summary and Discussion 
 
In this study, a reliable and reproducible method for creating an enriched 
TIC population for canine osteosarcoma was developed. It was demonstrated 
that these TICs can be targeted with vismodegib and lapatinib. Most importantly, 
these results support beginning clinical trials in dogs with spontaneous 
osteosarcoma to determine if smoothened-inhibiting or HER2-targeting drugs 
will have an effect on metastases. 
 
Tumor-initiation cells 
Canine osteosarcoma is not only an ideal model for human 
osteosarcoma, but possibly for general TIC pathogenesis as well. Osteosarcoma 
can be difficult to diagnose due to its wide range in osteoid production and 
cellular morphology. In addition, the cancerous cells may redifferentiate to begin 
producing chondroid or fibrous looking cells. It is purely speculation, but the 
morphology of increasingly aggressive osteosarcomas follows the same pattern 
of what is known about TIC progression. It would be interesting to determine the 
TIC profiles of clearly differentiated osteosarcomas versus osteosarcomas with 
two or more mesenchymal cell morphologies versus aggressive anaplastic 
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osteosarcomas. Tumor features may direct treatment in osteosarcoma patients 
in the future, as is the case with non-Hodgkin’s lymphoma and breast cancer. 
Cancers from humans have more reliable surface markers for TIC 
isolation. In addition, human cancers have reliable side populations when 
processed with aldehyde dehydrogenase or Hoechst methods. In contrast, 
canine cancers are more limited for TIC isolation procedures. Before optimizing 
the epirubicin protocol, other methods were used on the canine osteosarcoma 
cell lines. The surface markers CD34 molecule (CD34), CD44, CD133, and 
ABCG2 were used to attempt to isolate TICs through magnetic bead sorting and 
flow cytometry. None of these surface markers reliably separated out the TIC 
population. Sarcosphere culture was also attempted, but despite using very low 
seeding concentrations the cells would aggregate. This confounded the results. 
The aldehyde dehydrogenase assay was also used to attempt to identify the TIC 
subpopulation, but as other have reported, the canine cells did not work well with 
the Aldefluor kit [246]. Epirubicin treatment was the only method that reliably 
produced a TIC-enriched population for study. 
Some would argue that an “enriched population” is not appropriate for 
study and that it is necessary to produce a uniform population of TICs. If the goal 
is to identify incredibly delicate facts about TICs, such as genome differences 
from other cells within the tumor, then yes, a clean population is needed. In this 
case, the goal was to find drugs that target these cells for death. A slightly mixed 
population of cells still produces data similar to what would be seen in a pure 
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population. This is enough information to move forward towards getting more 
treatment options to patients, instead of getting hung up in the details.  
With epirubicin treatment, there was a slight difference between the 
number of cells killed off in the Calcein AM assay versus the AO/PI viability 
assay. The Calcein AM assay predicted that around 50% of the cells would be 
killed at 2 μg/ml. This number was expected to be lower when treated in serum-
free medium in an anchorage-independent manner. This may indicate that harsh 
culture conditions activated mechanisms for cell plasticity leading to increased 
survival. The switch from undetectable NANOG to a higher proportion of cells 
expressing NANOG also supports this notion.  
There was considerable fluctuations in gene expression when the TICs 
were analyzed over one week. This further demonstrates the plasticity of these 
cells and reminds scientists to analyze their data spatially. Based on the results 
of NANOG, these osteosarcoma cell lines have a plastic population of TICs. 
OCT4 was barely detected in the unenriched cell populations, and NANOG was 
not detected. It was incredibly difficult to design primer pairs that were specific to 
OCT4 in the dog. Numerous pairs of published primers were evaluated, but once 
the product was sequenced it was revealed that the OCT4 pseudogene was 
targeted instead. It appears that the predicted sequences for OCT4 and the 
OCT4 pseudogene in the National Center for Biotechnology Information 
database may be incorrect. Personally designed primers using the OCT4 
sequence from the database also resulted in targeting the pseudogene. It is 
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important for the OCT4 gene and any paralogs to be properly sequenced before 
OCT4 can be reliably used as a marker for stemness in dogs. There are 
alternative theories where the gene database is correct. In humans, a NANOG 
paralog is responsible for most cancers [190-196]. A NANOG pseudogene has 
not been identified in dogs, yet dogs have a higher cancer rate compared to 
humans. OCT4 is the first upstream gene responsible embryogenesis, so in 
cancer it should play a more aggressive role than NANOG. Perhaps the gene 
database is correct, but canine cancers upregulate the OCT4 psudeogene 
similar to human cancers utilizing the NANOG pseudogene. If this is the case, it 
could explain why dogs have a higher cancer rate than humans. A second 
alternative reason for the primers not working properly is cell culture alteration. 
Possibly over years of passages OCT4 has mutated in canine osteosarcoma cell 
lines. 
Perhaps the most exciting information about this canine model of 
osteosarcoma is the evidence of quiescence. In both human and canine 
osteosarcoma the goal is to target cells that have metastasized and remained 
stealthed. Other in vitro models of osteosarcoma isolated TICs and then 
immediately demonstrated aggressive replication. The canine osteosarcoma 
model with epirubicin selection pushed cells into quiescence and this mimics 
what is seen clinically. The cells went into quiescence to protect themselves, 
with evidence of p21 upregulation. Conditions were improved with daily medium 
changes. Three to five days later, the cells exited quiescence as shown by 
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decreased p27. The amount of NAONG was diluted as the cells began 
repopulating the differentiated tumor cell population. This is an accelerated 
model of osteosarcoma TIC plasticity and quiescence, which is what is 
presumed to take place during metastasis. Others have suggested a treatment 
strategy of driving the cells out of quiescence so that cytotoxic drugs will affect 
them [144]. Lapatinib increased the mitotic rate within solid tumors. This should 
be explored further to determine if targeting HER2 drives TICs out of 
quiescence, making them subsequently more susceptible to other more 
traditional therapies.  
Other experiments were attempted, but did not properly work on canine 
TICs. Western blots were attempted with mixed results. The antibodies that did 
not work with TIC isolation assays gave too much non-specific signal on western 
blot analysis. Antibodies to intracellular targets, such as NANOG, were also 
disappointing. Invasion assays were also attempted to determine the drug 
potential to inhibit metastasis. The canine osteosarcoma cell lines were far too 
aggressive, which confounded the data. Finally, cells and TICs were irradiated to 
determine if TICs could repair DNA faster. A fluorescent antibody, anti-H2A 
histone family, member X was used to monitor DNA repair. The difference 
between groups was negligible, again possibly due to the aggressive nature of 
the cell lines used. This area of canine osteosarcoma TIC research would 
benefit from a comparison between established and early passaged cell lines. 
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 Smoothened-inhibition 
 Vismodegib showed the greatest potential as an inhibitor of 
osteosarcoma metastases. Future clinical studies should be designed so that 
the patient begins taking vismodegib at diagnosis and in combination with other 
recommended treatments. The mice were treated for three weeks or less using 
an accelerated model of pulmonary metastases. Long term vismodegib 
treatment in a human or dog, with a realistic rate of metastases, might result in 
better performance of vismodegib.  
The lungs from the mice were analyzed with two techniques in parallel. 
The most accurate method is digital analysis using multiple non-serial slides to 
give a three-dimensional representation of the pathology. This is very time 
consuming. Forensic researchers have developed species-specific primer pairs 
for DNA analysis [360]. The amount of canine DNA within the mouse lungs was 
able to be determined using this technology. It is slightly less accurate because 
the tissue blocks included the esophagus and trachea with the lungs. Despite 
this complication, the PCR data closely matched the pattern of the digital 
analysis. Plus the DNA analysis was 95% quicker. Future experiments planning 
to utilize DNA analysis should receive adequate tissue dissection to make this 
test even more accurate.  
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 HER2-inhibition 
The canine osteosarcoma biopsies evaluated were predominately 
positive for HER2. This is in agreement with the majority of human studies. In 
contrast, HER2 overexpression was not prognostic in dogs. Regardless, the 
identification of HER2 in so many cases supports using drugs like lapatinib in 
canine clinical trials.  
 
Concluding Remarks 
 
The future goal of this research is to merit beginning clinical trials in dogs 
with spontaneous osteosarcoma as a model for human osteosarcoma. Previous 
studies suggest that osteosarcoma micrometastases are present in up to 90% of 
canine osteosarcoma cases at the time of diagnosis. Even when these 
metastases are not visualized with radiographic techniques, experienced 
veterinarians understand that they are present. Metastases will grow months 
following amputation of the primary tumor. It makes sense to start TIC-inhibiting 
drugs at the time of diagnosis and prior to surgery, and to continue treatment, 
preferably in combination with chemotherapy or radiation, until the drugs are not 
effective. In patients where metastases are evident at diagnosis or in patients 
that are not a candidate for surgery (i.e. axial osteosarcoma), TIC-inhibiting 
drugs could intensify the effectiveness of adjuvant treatment. This is an exciting 
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new area of cancer research with prospective treatments that may bring relief 
from those suffering from osteosarcoma. 
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